Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose ifosfamide vs gemcitabine + docetaxel in relapsed osteosarcoma
2015-004762-28Phase 2Terminated
- Sponsor
- Italian Sarcoma Group
- Start
- Nov 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in osteosarcoma (OS) comparing High-dose ifosfamide with Gemcitabine + docetaxel (2 arms). Primary endpoint: 6-month progression-free survival. Started Nov 2020; status: terminated.
02
Drugs
ifosfamidegemcitabinedocetaxel
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on 2015-004762-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004762-28.